Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 2
1983 1
1985 2
1989 1
1991 4
1992 8
1993 7
1994 6
1995 5
1996 4
1997 4
1998 7
1999 1
2000 4
2001 5
2002 6
2003 7
2004 11
2005 15
2006 8
2007 6
2008 6
2009 16
2010 9
2011 16
2012 20
2013 17
2014 17
2015 16
2016 14
2017 6
2018 10
2019 16
2020 23
2021 26
2022 35
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Fuchs CS, et al. Among authors: rosales m. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10. JAMA Oncol. 2018. PMID: 29543932 Free PMC article. Clinical Trial.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Rugo HS, et al. Among authors: rosales mk. J Clin Oncol. 2023 Jan 10;41(2):198-205. doi: 10.1200/JCO.21.02937. Epub 2022 Nov 4. J Clin Oncol. 2023. PMID: 36332179 Free PMC article. Clinical Trial.
Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Gradishar WJ, et al. Among authors: rosales mk. Future Oncol. 2023 May;19(16):1099-1112. doi: 10.2217/fon-2022-1040. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170847 Free article. Review.
Eyeing the Fountain of Youth.
Saint-Geniez M, Rosales MAB. Saint-Geniez M, et al. Among authors: rosales mab. Cell Stem Cell. 2017 May 4;20(5):583-584. doi: 10.1016/j.stem.2017.04.007. Cell Stem Cell. 2017. PMID: 28475881 Free article.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. Catenacci DV, et al. Among authors: rosales mk. Oncology (Williston Park). 2023 Apr 25;37(4):176-183. doi: 10.46883/2023.25920992. Oncology (Williston Park). 2023. PMID: 37104758 Free article.
342 results